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Background. About 90% of thyroid cancers are differentiated thyroid cancers. Standard treatment is total thyroidectomy followed
by radioactive I131remnant ablation and TSH suppression with thyroxine. Unsuccessful ablation drastically affects the prognosis
of patients with DTC particularly high risk individuals; therefore, identifying the factors that affect the success of ablation is
important in the management of patients with DTC. sTg is a good predictor of successful ablation in DTC. Its levels can be
influenced by tumor staging andTSH values, as well as other factors.Therefore, we did this study using TSH to correct the predictive
value of sTg in success of RRA. Methods. We retrospectively reviewed the records of 75 patients with DTC, who underwent total
thyroidectomy followed by RRA and TSH suppression. Results. Preablation sTg and sTg/TSH ratio are significantly associated with
ablation outcome. Cutoff value for sTg to predict successful and unsuccessful ablationwas 18 ng/mLwith 76.7% sensitivity and 79.1%
specificity, while for sTg/TSH cutoff was 0.35 with 81.4% sensitivity and 81.5% specificity (𝑃 < 0.001). Association was stronger for
sTg/TSH ratio with adjusted odds ratio (AOR) 11.64 (2.43–55.61) than for sTg with AOR 5.42 (1.18–24.88). Conclusions. Preablation
sTg/TSH ratio can be considered as better predictor of ablation outcome than sTg, tumor size, and capsular invasion.
1. Introduction
Thyroid cancer is the most common endocrine tumor. About
90% of thyroid cancers are differentiated (papillary or follic-
ular) thyroid cancers [1]. Overall the prognosis in patients
with differentiated thyroid cancers (DTC) is good [2]. With
appropriate treatment, themajority of these patients get cured
except in patients with metastasis where the prognosis is
worse [2, 3]. Management of patients with differentiated
thyroid cancer involves total thyroidectomy followed by
radioactive I131remnant ablation (RRA), except in patients
with intrathyroidal tumor ≤ 1 cm in size [4, 5]. The RRA
may also be avoided in low risk well-differentiated thyroid
cancer with postsurgical stimulated thyroglobulin (sTg) <
1 ng/mL, an approach not yet approved by AmericanThyroid
Association (ATA) [6–8]. The theoretical goals of adjuvant
ablation are (a) to destroy any residual microscopic disease,
(b) to enhance sensitivity of diagnostic whole body iodine
scan (WBIS) and specificity of serum thyroglobulin (Tg)
which facilitates follow-up and early detection of recurrence
or metastatic disease, and (c) to use postablativeWBIS which
is more sensitive than diagnostic WBIS for detection of
nodal or distant functioning metastases [9]. According to
ATA guidelines, sTg and neck ultrasound with or without
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diagnostic WBIS should be done 6–12 months after RRA in
these patients to see the presence or absence of disease [4].
An area of ongoing controversy is the optimal dose of
RAI required to successfully ablate remnant tissue after total
or near-total thyroidectomy with a single administration in
low risk group. This can be achieved by either dosimetry
method introduced by Benua et al. or by fixed empiric activity
of RAI [10]. According to Maxon et al., about 30,000 rad
(300Gy) radiation dose to thyroid bed was required for
successful ablation and Bal CS and Padhy found 50mCi
(1850MBq) of RAI to deliver this required dose to thy-
roid bed after total thyroidectomy [11, 12]. However, due
to cumbersomeness of dosimetry method, the majority of
treating physicians have adopted fixed empiric activity of RAI
(30–200mCi or 1110–7400MBq) with no consensus about
adequate ablative dose in low risk patients [12]. Due to these
variable results, there has been lack of consensus among
various thyroid organizations on the optimum RAI dose
for remnant ablation in low risk group. The British Thyroid
Association’s 2007 guidelines recommend the use of high
dose RAI [13]. National Comprehensive Cancer Network
(NCCN; 2010 guidelines), the AmericanThyroid Association
(ATA; 2009 guidelines), and European Thyroid Cancer Task
Force consensus report (ETCTF; consensus report, 2006)
advise that clinicians can choose between the low dose and
the high dose due to lack of reliable evidence from large
randomized studies [14].
Tg is a well-recognized marker in the follow-up of
patients with differentiated thyroid cancers after thyroidec-
tomy for persistent disease, distant metastasis, or disease
recurrence [15–17]. sTg before RRA is a good predictor of
successful ablation in these patients [15, 18]. Its levels can be
influenced by tumor staging and TSH levels as well as other
factors. Therefore we did this study using TSH to correct the
predictive value of sTg in success of RRA. Our objective was
to see whether sTg/TSH ratio can be used as a good predictor
of successful RRA and to compare its predictability with
sTg.
2. Patients, Material, and Methods
Patients.We retrospectively reviewed themedical record of all
patients with DTC treated at the Section of Endocrinology,
Aga Khan University Hospital, Karachi, from 2003 to 2013.
An approval was obtained fromEthical ReviewCommittee of
Aga Khan University Hospital for this study. Only 75 patients
met our inclusion criteria.
Our inclusion criteria were as followed: (1) all adult
patients with DTC; (2) those who underwent total thyroidec-
tomy; (3) those having stimulated TSH (sTSH), sTg, and
Anti-Tg antibodies (Anti-Tg) 3-4 weeks after thyroidectomy
without thyroxine replacement; (4) those who received RRA;
(5)those having posttherapeuticWBIS; (6) those having neck
ultrasound, diagnostic WBIS, and sTg; and (7) Anti-Tg at
6–12 months after RRA. We excluded patients with (1) less
then total thyroidectomy, that is, subtotal thyroidectomy or
lobectomy; (2) diagnostic WBIS done before RRA because
of possible stunning effect and low sensitivity; (3) Anti-Tg
> 40 IU/mL prior to RRA as it might influence the absolute
value of sTg.
All 75 patients were treated as per following protocol: (1)
they underwent total thyroidectomy; (2) they were without
thyroxine replacement for 3-4 weeks following surgery; (3)
they were on low iodine diet for 2 weeks prior to RRA; (4)
they got their sTSH, sTg, and Anti-Tg done approximately
2-3 days prior to RRA; (5) they received RRA of 30 to
100mCi in ATA low risk, 150mCi in ATA intermediate risk,
and 200mCi in ATA high risk groups; (6) they got their
posttherapeutic WBIS done 3 to 5 days after RRA; (7) they
were started on thyroxine after RRA to suppress TSH below
0.1 in intermediate and high risk group and below 0.5 in low
risk group; and (8) they get their sTSH, sTg, Anti-Tg, neck
ultrasound, and diagnostic WBIS 6–12 months after RRA.
Diagnostic WBIS was performed 48 hours after giving 2mCi
of I131. We used dual head digital gamma camera (ECAM,
Siemens, Germany) for both posttherapeutic and diagnostic
WBIS.
We assessed the following variables as a possible predictor
of successful ablation: sTg before RRA, sTg/TSH ratio before
RRA, age, sex, RRA dose, postablative WBIS findings, TNM
staging, and histology (follicular or papillary).
Successful ablation is defined as sTg < 2 ng/mL with neg-
ative Anti-Tg antibodies, no evidence of tumor on diagnostic
WBIS as well as on neck ultrasound 6–12 months after RRA.
TSH was measured using Chemiluminescent assays with
analytical sensitivity of 0.008 uIU/mL, functional sensitiv-
ity of 0.008 uIU/mL, and reportable range of 0.008 to
150 uIU/mL. Tg was measured using Chemiluminescent
assays with analytical sensitivity of 0.2 ng/mL and functional
sensitivity of 0.9 ng/mL interassay for values higher than
2 ng/mL. Anti-Tg antibodies were measured using Chemi-
luminescent assays with analytical sensitivity of 2.2 IU/mL,
interassay precision of 4.6–5.8%, and intra-assay precision
of 3.2–4.9% with reportable range of 20–3000 IU/mL and
normal range < 40 IU/mL.
3. Statistical Analysis
Data was entered and analyzed using SPSS version 19.0.
Comparative analysis was done using student’s t-test or
Wilcoxon Rank sum test for continuous variables and chi-
square test for categorical variables. Cutoff values of serum
preablation sTg and sTg/TSH were determined and receiver
operating characteristic (ROC) curves were generated using
ROC analysis. Values with maximum sensitivity and speci-
ficity were selected to define cutoff values. Univariate and
multivariate logistic regression were performed to see the
predictors of successful ablation. For the analysis 𝑃 value less
than 0.05 was considered significant.
4. Results
Records of 75 patients who fulfilled our criteria were
retrieved. Out of these 60% (45) had successful ablation,
while 40% (30) had unsuccessful ablation. There was no sig-
nificant difference between two groups, that is, patients with
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successful ablation and unsuccessful ablation with respect to
age and gender. Most of the tumors were papillary carcino-
mas 91.9% and 90% in successful and unsuccessful groups,
respectively. Similarly no statistically significant differences
were found between the two groups in size of tumor, cap-
sular invasion, pathological and TNM tumor stages, lymph
node involvement, ATA risk, and the dose of radioactive
iodine given. However more distant metastasis was seen in
unsuccessful group as compared to successful group and this
difference was statistically significant. There was also signif-
icant difference in lower median levels of sTg and sTg/TSH
ratio in patients with successful and unsuccessful ablation;
that is, lower median level of sTg is 3.05 (0.20–14.5) among
patients with successful ablation, whereas it is 140 (17.65–
689) among patients with unsuccessful ablation. Similarly
lower median level of sTg/TSH ratio is 0.067 (0.005–0.26)
among patients with successful ablation compared to 2.84
(0.366–22.61) among unsuccessful ablation group. 76.6% of
unsuccessful group patients had sTg levels > 18 ng/mL as
compared to 24.4% in successful group. Similarly more of
unsuccessful group patients, that is, 80% of unsuccessful
group patients, had sTg/TSH ratio > 0.35 against 20.5% in
successful group (Table 1).
Cutoff value for sTg to predict successful and unsuccess-
ful ablation was 18 ng/mL with 76.7% sensitivity and 79.1%
specificity, while for sTg/TSH cutoff was 0.35 with 81.4%
sensitivity and 81.5% specificity. These cutoff values were
used in all the analysis (Table 2). ROC curve for accuracy is
illustrated in Figure 1, showing sensitivity and specificity for
different cutoff values of sTg and sTg/TSH ratio (Figure 1).
Univariate logistic regression found no significant asso-
ciation of ablation outcome with age, gender, tumor size,
capsular invasion, distant metastasis, and ETA risk. How-
ever lymph node involvement, sTg levels > 18 ng/mL, and
sTg/TSH ratio > 0.35 were significantly associated with
unsuccessful ablation (Table 3). Similar trend persisted in
multivariate analysis and only sTg levels and sTg/TSH ratio
remained significantly associated with unsuccessful ablation.
Association was stronger for sTg/TSH ratio with AOR
11.64 (2.43–55.61) than for sTg with AOR 5.42 (1.18–24.88)
(Table 4).
5. Discussion
Unsuccessful ablation may adversely affect the prognosis of
patients with DTC; therefore, identifying the factors that
affect the success of ablation is very important in themanage-
ment of patients with DTC.
Thyroglobulin is a large glycoprotein with molecular
weight of 660,000 Daltons containing >3000 amino acids
[19]. It is produced in the endoplasmic reticulum of thyroid
follicular cells and stored in theGolgi apparatus to be secreted
in thyroid follicular lumen [19]. TSH stimulation leads to
intracellular reuptake of thyroglobulin and its proteolytic
degradation into active forms of thyroid hormones, that
is, triiodothyronine and thyroxine [20]. Initially Tg was
thought to exist in the thyroid gland only but in 1961 its
presence was demonstrated in the peripheral circulation too
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Figure 1: ROC curve of the accuracy of serum preablation sTg and
sTg/TSH ratio in predicting unsuccessful ablation.
as a byproduct of thyroid hormone synthesis [21]. In healthy
individuals, small amount of Tg is released physiologically
into the circulation but in DTC it is actively released into
circulation [20]. As Tg is actively released into circulation
by DTC, therefore its level in circulation following total
thyroidectomy is an established method of detecting recur-
rent or persistent disease particularly when performed after
thyroxine withdrawal or recombinant TSH administration
[22–26]. Measurement of serum Tg becomes an important
parameter for residual or recurrent disease in the follow-up
of patients with DTC following total thyroidectomy and RRA
[4, 23, 24].
Predicting the outcome of ablation in patients with DTC
is important as this can help make appropriate decisions for
patient’s management. Previous studies have focused on sTg
only as a laboratory parameter for predicting the ablation
outcome [16, 27]. A recent retrospective study conducted
on 133 patients revealed that a preablation sTg < 8.55 ug/L
predicted disease remission after 18–24 months of RRA with
sensitivity of 88%, specificity of 72%, positive predictive value
(PPV) of 47%, and negative predictive value (NPV) of 95%
[18]. Another study conducted on 96 patients in Brazil found
that patients with sTg levels < 18 ng/mL before RRA had
5.89 times greater chance of successful ablation compared to
those with sTg > 18 ng/mL (𝑃 < 0.0001) with sensitivity of
71.4%, specificity of 70.2%, PPV of 71.4%, and NPV of 70.2%
[16]. Another recent study conducted in China showed that
in patients with DTC who underwent total thyroidectomy,
sTg and its ratio with TSH before RRA might be considered
as predictive markers for metastasis [1]. We used diagnostic
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Table 1: Comparison of baseline characteristics of successful and unsuccessful ablation.
Characteristic Successful ablation% (𝑛)
Unsuccessful ablation
% (𝑛) 𝑃 value
Age
40 or less 44.4 (20) 53.3 (16) 0.45
More than 40 55.6 (25) 46.7 (14)
Gender
Male 42.2 (19) 43.3 (13) 0.924
Female 57.8 (26) 56.7 (17)
Histopathological types
Papillary carcinoma 91.9 (41) 90.0 (27) 0.871
Follicular carcinoma 8.9 (4) 10.0 (3)
Size of tumor
>4 cm 77.8 (35) 63.3 (19) 0.172
<4 cm 22.2 (10) 36.7 (11)
Capsular invasion
Yes 15.6 (7) 33.3 (10) 0.072
No 84.4 (38) 66.7 (20)
Pathological tumor stage
pT1 40 (18) 33.3 (10) 0.297
pT2 33.3 (15) 20.0 (6)
pT3 17.8 (8) 26.7 (8)
pT4 8.9 (4) 20.0 (6)
LN involvement
N1a 8.9 (4) 23.3 (7) 0.064
N1b 33.3 (15) 23.3 (7)
Nx 28.9 (13) 43.3 (13)
No 28.9 (13) 10.0 (3)
Distant metastasis
M0 95.6 (43) 86.7 (18) 0.170
M1 2 (4.4) 13.3 (4)
TNM stage
Stage 1 75.6 (34) 53.3 (16) 0.061
Stage 2 2.2 (1) 6.7 (2)
Stage 3 8.9 (4) 3.3 (1)
Stage 4 13.3 (6) 36.7 (11)
ETA risk
Low risk 42.2 (19) 27.6 (8) 0.168
Intermediate risk 11.1 (5) 6.7 (2)
High risk 46.7 (21) 66.7 (20)
RAI dose
30–100mCi 75.5 (34) 70 (21) 0.094
150mCi 24.4 (11) 20 (6)
200mCi 0 10 (3)
sTg
Median (IQR) 3.05 (0.20–14.5) 140 (17.65–689) <0.001
Preablation sTg
≤18 ng 75.6 (34) 23.3 (7) <0.001
>18 ng 24.4 (11) 76.6 (23)
TG/TSH
Median (IQR) 0.067 (0.005–0.26) 2.84 (0.366–22.61) <0.001
sTg/TSH
≤0.35 79.5 (35) 20 (6) <0.001
>0.35 20.5 (9) 80 (24)
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Table 2: Cutoff values∗ for sTg and sTg/TSH ratio with sensitivity and specificity.
Predictor Sensitivity Specificity Area under curve 𝑃 value
sTg
≤18 ng/mL 76.7% 79.1% 0.86 <0.001
sTg/TSH ratio
≤0.35 80% 81.4% 0.859 <0.001
∗Values with maximum sensitivity and specificity.
Table 3: Univariate analysis of various patient and tumor character-
istics and unsuccessful ablation.
Variable OR (95% CI) 𝑃 value
Age
40 or less 1
More than 40 0.7 (0.28–1.77) 0.457
Gender
Male 1
Female 0.96 (0.38–2.43) 0.924
Size of tumor
>4 cm 1
<4 cm 2.02 (0.73–5.63) 0.176
Capsular invasion
No 1
Yes 2.71 (0.90–8.21) 0.077
Lymph node involvement
No 1
N1a 7.58 (1.31–43.92) 0.024
N1b 2.02 (0.43–9.6) 0.371
Nx 4.33 (0.99–18.87) 0.051
Distant metastasis
M0 1
M1 3.31 (0.57–9.34) 0.18
ETA risk
Low risk 1
Intermediate risk 0.95 (0.15–5.96) 0.956
High risk 2.26 (0.81–6.32) 0.120
sTg
≤18 ng 1
>18 ng 11.17 (3.71–33.61) <0.001∗
sTg/TSH
≤0.35 1
>0.35 15.56 (4.9–49.44) <0.001∗
∗
𝑃-value < 0.005.
WBIS as an exclusion criterion due to its low impact on the
decision to ablate and because of concerns over 131I induced
stunning of normal thyroid remnants and distant metastases
from thyroid cancer [4].
This is first attempt to assess the association of sTg/TSH
ratio with ablation outcome, which was found to be sig-
nificantly associated with ablation outcome than sTg. In
this study, factors such as age, gender, type of tumor, size
of tumor, and capsular invasion were not found to be
significantly associated with RRA outcome, while sTg levels
Table 4: Multivariate analysis of sTg levels, sTg/TSH ratio, and
unsuccessful ablation.
Variable AOR (95% CI) 𝑃 value
sTg
≤18 ng 1
>18 ng 5.42 (1.18–24.88) 0.030
sTg/TSH
≤0.35 1
>0.35 11.64 (2.43–55.61) <0.001
AOR: adjusted odds ratio.
are significantly associated, a finding which is consistent
with other studies [1, 27–31]. Important finding of our study
is association of sTg/TSH ratio with ablation outcome. We
found that sTg/TSH ratio had stronger association with
ablation outcome than sTg. As sTg/TSH ratio was found to
be significantly associated with ablation outcome; therefore,
it can help us in predicting the success of RRA and we
hypothesized that it might also help in adjusting the dose of
I131. This adjustment in the dose of I131remnant ablative dose
might be very important particularly in low risk DTC where
there is still no consensus on optimal dose.
We also defined the appropriate cutoff values for these two
predictors. Cutoff value of 18 ng/mL for sTg from our study is
consistent with other studies from Brazil, but our sensitivity
and specificity are higher than those reported earlier for
cutoff value of 18 ng/mL [16]. Since no cutoff value for
sTg/TSH ratio was available; therefore, we also determined
cutoff value for sTg/TSH ratio, that is, 0.35 for predicting
ablation outcome. These cutoff values for sTg and sTg/TSH
ratio in our study have high sensitivity and specificity in
predicting the outcome.
This study is one of its kinds, investigating the association
of sTg/TSH ratio with ablation outcome in patients with
DTC. We found that patients with sTg/TSH ratio < 0.35
before RRA had 11.64 times greater chance of successful
ablation compared to those with sTg/TSH ratio > 0.35 with
sensitivity of 80.0% and specificity of 81.4% (𝑃 < 0.001).
However limitation of our study was its retrospective nature;
therefore, we could retrieve data of only 75 patients who
fulfilled our inclusion criteria. Many of the previous studies
regarding role of sTg in predicting RRA outcome were
also retrospective in nature [8, 15, 16, 18, 29, 31]. Another
limitation of this study is use of different ablative doses
in low, intermediate, and high risk groups which could
have an impact on success of ablation as British Thyroid
Association 2007 guidelines favor use of high dose for RRA
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[13]. Our data do not show a significant impact of dose of
RRA upon outcome and this is in concordance with two
recently published prospective trials claiming no difference
in outcomes in patients treated with 30 and 100mCi RRA
(32,33). Because of its smaller sample size, the result of this
study should be interpreted cautiously and we recommend
further studies not only to validate the cutoff levels that we
have set but also to confirm the other findings of this study.
6. Conclusion
Our study adds to the value of preablation sTg and establishes
the role of preablation sTg/TSH ratio in predicting the
ablation outcome. One of the suggestions that came out from
this study is that preablation sTg/TSH ratiomight be used for
risk stratification, as till now there is no laboratory parameter
in the risk stratification of the ATA and ETA for DTC before
ablation. So patients with sTg/TSH ratio >0.35 can be placed
in ATA and ETA high risk categories as sTg/TSH ratio has
even more significant association with RRA outcome than
size and capsular invasion. However considering the limited
sample size in this study, further studies are warranted to
confirm these findings.
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